GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Baxter International Inc (NYSE:BAX) » Definitions » EV-to-EBIT
中文

Baxter International (Baxter International) EV-to-EBIT

: 68.95 (As of Today)
View and export this data going back to 1961. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Baxter International's Enterprise Value is $32,063 Mil. Baxter International's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $465 Mil. Therefore, Baxter International's EV-to-EBIT for today is 68.95.

The historical rank and industry rank for Baxter International's EV-to-EBIT or its related term are showing as below:

BAX' s EV-to-EBIT Range Over the Past 10 Years
Min: -2937.1   Med: 29.26   Max: 77.84
Current: 68.95

During the past 13 years, the highest EV-to-EBIT of Baxter International was 77.84. The lowest was -2937.10. And the median was 29.26.

BAX's EV-to-EBIT is ranked worse than
89.46% of 465 companies
in the Medical Devices & Instruments industry
Industry Median: 19.86 vs BAX: 68.95

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Baxter International's Enterprise Value for the quarter that ended in Dec. 2023 was $30,861 Mil. Baxter International's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $465 Mil. Baxter International's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 1.51%.


Baxter International EV-to-EBIT Historical Data

The historical data trend for Baxter International's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baxter International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.61 30.19 44.19 -18.46 75.45

Baxter International Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.46 -16.73 -15.31 76.45 75.45

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Baxter International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baxter International EV-to-EBIT Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Baxter International's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Baxter International's EV-to-EBIT falls into.



Baxter International EV-to-EBIT Calculation

Baxter International's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=32063.414/465
=68.95

Baxter International's current Enterprise Value is $32,063 Mil.
Baxter International's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $465 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Baxter International  (NYSE:BAX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Baxter International's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=465/30861.09178
=1.51 %

Baxter International's Enterprise Value for the quarter that ended in Dec. 2023 was $30,861 Mil.
Baxter International's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $465 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Baxter International EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Baxter International's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Baxter International (Baxter International) Business Description

Address
One Baxter Parkway, Deerfield, IL, USA, 60015
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.
Executives
Joel T. Grade officer: EVP, Chief Financial Officer SYSCO CORPORATION, 1390 ENCLAVE PARKWAY, HOUSTON TX 77077
Stephen H Rusckowski director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ampofo William A. Ii director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Christopher A. Toth officer: EVP, Group Pres, Kidney Care 1252 COOLIDGE AVE., SAN JOSE CA 95125
Stroucken Albert P L director BAXTER INTERNATIONAL INC., ONE BAXTER PARKWAY, DEERFIELD IL 60015
Reaz Rasul officer: EVP, Group Pres, Healthcare ONE BAXTER PARKWAY, DEERFIELD IL 60015
Alok Sonig officer: EVP, Group President, Pharm ONE BAXTER PARKWAY, DEERFIELD IL 60015
Heather Knight officer: EVP, Group Pres, Medical ONE BAXTER PARKWAY, DEERFIELD IL 60015
Jacqueline Kunzler officer: SVP, Chief Quality Officer ONE BAXTER PARKWAY, DEERFIELD IL 60015
Jeanne K Mason officer: CVP, Human Resources ONE BAXTER PARKWAY, DEERFIELD IL 60015
Steven Flynn officer: SVP, President, APAC ONE BAXTER PARKWAY, DEERFIELD IL 60015
Peter M Wilver director
David Brent Shafer director 2800 ROCKCREEK PARKWAY, NORTH KANSAS CITY MO 64117
Amy Mcbride Wendell director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Cathy R Smith director TARGET CORPORATION, 1000 NICOLLET MALL, TPS-3155, MINNEAPOLIS MN 55403